SRN Advisors LLC Buys Shares of 1,380 Zoetis Inc. (NYSE:ZTS)

SRN Advisors LLC purchased a new position in shares of Zoetis Inc. (NYSE:ZTS) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 1,380 shares of the company’s stock, valued at approximately $225,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Hancock Whitney Corp increased its holdings in Zoetis by 0.3% during the 3rd quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock valued at $3,628,000 after purchasing an additional 61 shares in the last quarter. Strategy Asset Managers LLC grew its holdings in shares of Zoetis by 3.5% during the third quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock worth $356,000 after purchasing an additional 62 shares during the last quarter. VeraBank N.A. increased its stake in shares of Zoetis by 4.1% in the fourth quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock valued at $254,000 after buying an additional 62 shares in the last quarter. Procyon Advisors LLC raised its holdings in shares of Zoetis by 1.4% in the fourth quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock valued at $768,000 after buying an additional 63 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators lifted its position in Zoetis by 6.6% during the 4th quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company’s stock worth $170,000 after buying an additional 65 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Performance

ZTS stock opened at $164.99 on Thursday. The business’s fifty day moving average is $166.22 and its 200-day moving average is $177.58. The company has a market cap of $73.88 billion, a P/E ratio of 30.16, a price-to-earnings-growth ratio of 2.78 and a beta of 0.90. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. The business had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Equities research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.21%. Zoetis’s dividend payout ratio (DPR) is currently 36.56%.

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now directly owns 16,107 shares in the company, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

ZTS has been the subject of several research reports. Piper Sandler lowered their price objective on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. StockNews.com cut shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Tuesday. UBS Group started coverage on shares of Zoetis in a research report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective for the company. Morgan Stanley reduced their price objective on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Finally, Stifel Nicolaus lowered their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Two investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $215.40.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.